Cidara Therapeutics, Inc.
CDTXDelisted Jan 7, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001610618
Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.
Q1 2025 vs. Q4 2024
How the institutions holding Cidara Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 40 | 46 | +6 |
| Shares | 6.87M | 9.56M | +2.69M (+39.1%) |
| Value | $183.6M | $205.9M | +$22.3M (+12.1%) |
New holders (8)
Institutions that held Cidara Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vestal Point Capital, LP | 504,542 | $10.9M | 0.78% |
| Citadel Advisors LLC | 287,775 | $6.20M | 0.01% |
| Standard Life Aberdeen plc | 120,879 | $2.60M | 0.01% |
| Sphera Funds Management Ltd. | 17,128 | $368.9K | 0.09% |
| West Michigan Advisors, LLC | 13,500 | $290.8K | 0.10% |
| American Century Companies Inc | 10,409 | $224.2K | 0.00% |
| Tower Research Capital LLC (TRC) | 933 | $20.1K | 0.00% |
| Barclays PLC | 28 | $603 | 0.00% |
Sold out (2)
Institutions that held Cidara Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| StemPoint Capital LP | 47,642 | $1.28M |
| Manchester Capital Management LLC | 470 | $12.6K |